Adare Pharmaceuticals
Adare Pharmaceuticals is a global technology-driven specialty CDMO providing turnkey product development through to commercial manufacturing expertise focused on oral dosage forms for the pharmaceutical, animal health and OTC markets. Adare’s proprietary technology platforms specialise in ODT’s, taste masking and customised drug release.
In 2020 Adare acquired Orbis Biosciences, broadening its oral delivery technology portfolio and also moving into the field of injectables for the first time.
Adare was formed in 2015 when TPG Capital acquired and renamed Aptalis, but the company has 30 years of proven legacy with roots in companies such as Eurand and Aptalis. Adare has multiple facilities in the US and Europe, and has developed and manufactured more than 40 products sold by partners in more than 100 countries globally.